Clinical trials: Autologous Transplantation
Multiple Myeloma
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide…
- Trial name
- MajesTEC-4 (NCT05243797)
- Testing
- Teclistamab, Lenalidomide
- Where
- 212 sites in United States, Argentina and 23 more
- Volunteers
- 1,594 people
- Sponsor
- European Myeloma Network B.V.
Stage II Multiple Myeloma, Stage III Multiple Myeloma
Vaccine Therapy in Treating Patients With Multiple Myeloma
RATIONALE: Vaccines made from a person's tumor cells may make the body build an immune response and kill their tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Trial name
- NCT00019097
- Testing
- autologous tumor cell vaccine, keyhole limpet hemocyanin, melphalan
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Submandibular Gland Stem Cell Transplantation
This study is a phase I safety and feasibility study to treat head and neck cancer patients with autologous salivary gland stem cell transplantation after postoperative (chemo)radiotherapy.
- Trial name
- RESTART (NCT04593589)
- Testing
- Submandibular Gland Stem Cell Transplantation
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- University Medical Center Groningen
Diffuse Large B-cell Lymphoma(DLBCL)
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
The objective of this study is to evaluate the efficacy and safety of the Glofitamab bridging ASCT regimen in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and to provide better clinical benefits…
- Trial name
- ASCT DLBCL (NCT06682130)
- Testing
- Group A：Patients with PR or ctDNA positivity after salvage treatment, Group B: Patients with CR and ctDNA negative after salvage treatment, Group C: Patients with SD/PD after posterior treatment
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lymphoma, Large-Cell, Diffuse
ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma
The primary objective of the study is to evaluate the efficacy of ASCT as consolidation in case of bcl-2 overexpression in non previously treated patients aged 60 years or less with low-intermediate risk diffuse large B-cell…
- Trial name
- NCT00169130
- Testing
- doxorubicin, cyclophosphamide, Autologous stem cell transplantation
- Where
- 5 sites in Belgium, France
- Volunteers
- 300 people
- Sponsor
- Lymphoma Study Association
Peripheral Vascular Diseases
Bone Marrow Autograft in Limb Ischemia
BALI (Bone marrow Autograft in Limb Ischemia) is a randomized double-blind trial comparing implantation of bone marrow - mononuclear cells versus placebo in patients presenting with critical leg ischemia and no surgical option.
- Trial name
- BALI (NCT00904501)
- Testing
- Bone marrow harvest
- Where
- 15 sites in France
- Volunteers
- 40 people
- Sponsor
- CHU de Reims
Limbal Stem Cell Deficiency Due to Ocular Burn
Follow-up Study After ACLSCT for Restoration of Corneal Epithelium in Patients With LSCD Due to Ocular Burns
This is a multinational, multicentre, prospective, non-pharmacological follow-up study of the clinical trial HOLOCORE. All patients transplanted with Holoclar in the HOLOCORE clinical trial who consent to participate will be…
- Trial name
- HOLOCORE-FU (NCT03288844)
- Testing
- Ophthalmologic examinations, Digital pictures, QoL Questionnaires
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- Holostem s.r.l.
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide [RICE], rituximab, cytarabine, dexamethasone, oxaliplatin or…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements
- Trial name
- NCT06905509
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Davis
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182793
- Testing
- trastuzumab, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Central Nervous System Neoplasms, Neoplasm Metastasis
Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy
The goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors. Past studies showed that the maximum dose of temozolomide was limited by low blood counts.
- Trial name
- CN-306 (NCT00629187)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Tufts Medical Center
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Autologous Haemopoietic Stem Cell Transplant
Nutrition OUtReach In Systems of Healthcare
Many children and adults receiving medical treatments have higher costs, which can make it harder for them to afford groceries. When someone can't afford enough food, and they do not receive proper nutrition it can make treatment…
- Conditions
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Autologous Haemopoietic Stem Cell Transplant, CAR-T Cell Therapy, Food Insecurity
- Trial name
- NOURISH (NCT06802406)
- Testing
- Food Bags
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- University of Kansas Medical Center
Leukemia
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to…
- Trial name
- NCT00002514
- Testing
- sargramostim, asparaginase, cyclophosphamide
- Where
- 94 sites in United States
- Volunteers
- 1,929 people
- Sponsor
- Eastern Cooperative Oncology Group
Complete Spinal Cord Injuries
Transplantation of Autologous Olfactory Ensheathing Cells in Complete Human Spinal Cord Injury
The purpose of this experimental therapy is an assessment of the safety and feasibility of transplantation of autologous olfactory ensheathing glia and olfactory fibroblasts obtained from the olfactory mucosa in patients with…
- Trial name
- NCT01231893
- Testing
- olfactory mucosa ensheathing cell grafting, rehabilitation, rehabilitation
- Where
- Poland
- Volunteers
- 10 people
- Sponsor
- Wroclaw Medical University
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to other treatments (salvage therapy) before…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Trial name
- NCT07365306
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- City of Hope Medical Center
Lymphoma
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
RATIONALE: Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, and chemotherapy, such as cyclophosphamide, helps stem cells move from the patient's bone marrow to the blood so they can be…
- Trial name
- NCT00242996
- Testing
- filgrastim, rituximab, sargramostim
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Amyloidosis
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
This randomized phase III trial is studying the side effects and how well giving induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation (ASCT) compared with ASCT alone in treating…
- Trial name
- NCT01998503
- Testing
- Bortezomib, dexamethasone, filgrastim
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Nanjing University School of Medicine
Multiple Sclerosis
Mesenchymal Stem Cell Transplantation in MS
The study is a randomized Phase II study, masked and crossed-over with placebo to evaluate the safety and tolerability of autologous mesenchymal stem cell transplantation in patients with active multiple sclerosis
- Trial name
- CMM-EM (NCT01228266)
- Testing
- autologous mesenchymal stem cells
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- Albert Saiz
B-cell Non Hodgkin Lymphoma
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
This is a single-center, open-label, prospective study enrolling high-risk (tumor diameter > 4 cm) relapsed/refractory B-NHL patients ineligible for HDCT and ASCT.
- Trial name
- NCT06646666
- Testing
- All-trans retinoic acid, zanubrutinib, radiotherapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Ruijin Hospital
Epilepsy
Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy
This research investigates the use of autologous bone marrow stem cells for the treatment of medically refractory temporal lobe epilepsy patients.
- Trial name
- NCT00916266
- Testing
- Stem cell transplantation
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Instituto do Cerebro de Brasilia
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
The study is an investigator-run, open-label Phase 1 safety study of autologous mesenchymal stem cell transplantation, involving approximately 24 ambulatory participants with relapsing forms of MS (approximately equal numbers…
- Conditions
- Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT00813969
- Testing
- Autologous mesenchymal stem cell transplantation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The Cleveland Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.